Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 18;23(1):329.
doi: 10.1186/s12935-023-03132-0.

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker

Li Li #  1 , Yixin Tong #  2 , Jianhong Wu  3 , Xiangshang Xu  4
Affiliations
Review

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker

Li Li et al. Cancer Cell Int. .

Abstract

Cervical cancer is a leading cause of gynecological cancer death in the world. Human papillomavirus (HPV) is the most causative factor of cervical cancer. In addition, many genetic factors are involved in cervical cancer development. Most studies focus on cervical samples to do research work about cervical cancer and precancerous lesions, but no sensitive or specific biomarkers were found. High-throughput genomic technologies are able to capture information from tumors and precancerous lesions in blood, thus providing a new way for the early diagnosis of cervical precancer and cervical cancer. Blood is an ideal specimen for detecting cancer biomarkers because it contains a lot of information, such as circulating tumor cells and circulating tumor DNA (ctDNA). This article reviews the clinical use and challenges of blood ctDNA testing in patients with cervical precancer and cervical cancer.

Keywords: Biomarker; Cervical cancer; HPV; ctDNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. WHO. : Launch of the Global Strategy to Accelerate the Elimination of Cervical Cancer. 2020.
    1. Pimple S, Mishra G. Cancer cervix: epidemiology and Disease burden. CytoJournal. 2022;19:21. - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. - PubMed
    1. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, Hosseini R, Eskandari N. An update on human papilloma virus vaccines: history, types, Protection, and Efficacy. Front Immunol. 2021;12:805695. - PMC - PubMed
    1. Murillo R, Ordonez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2019;29(8):1317–26. - PubMed

LinkOut - more resources